Iterum Therapeutics plc
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Corey N. Fishman
- Full Time Employees
- 9
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Fitzwilliam Court Dublin Ireland 2
- IPO Date
- May 25, 2018
- CIK
- 0001659323
- Website
- iterumtx.com
- Similar Companies
- Business
- Iterum Therapeutics plc, a clinical-stage pharmaceutical company founded in 2015 and headquartered in Dublin, Ireland, develops and commercializes differentiated anti-infectives targeting multi-drug resistant bacterial pathogens, with U.S. operations in Chicago, Illinois. The company focuses on sulopenem, a novel penem anti-infective available in oral and intravenous formulations that demonstrates potent in vitro activity against a broad spectrum of gram-negative, gram-positive, and anaerobic bacteria resistant to other antibiotics; its lead product, ORLYNVAH (oral sulopenem), is FDA-approved for treating uncomplicated urinary tract infections (uUTIs) caused by designated microorganisms including Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options. ORLYNVAH represents the first and only approved oral penem in the United States, addressing a critical need in community and hospital settings for infections driven by quinolone non-susceptible or multi-drug resistant pathogens. In June 2025, Iterum entered a Product Commercialization Agreement with EVERSANA Life Science Services, LLC, under which EVERSANA provides integrated sales, marketing, logistics, channel management, regulatory, and medical affairs services to support the U.S. launch of ORLYNVAH by the fourth quarter of 2025. The company commercially launched ORLYNVAH in the United States in 2025, marking the first branded oral antibiotic launch for uUTIs in over 25 years and extending its cash runway into the second quarter of 2026 through recent funding measures. Iterum operates in the biotechnology sector within the healthcare industry, serving patients and prescribers affected by serious infectious diseases globally, with primary emphasis on the U.S. market.
Iterum files wind-up petition due to limited cash, inability to raise equity
Iterum Therapeutics Announces Filing of Winding Up Petition
Iterum Therapeutics Provides Business Update
Iterum Therapeutics Provides Business Update
Iterum Therapeutics Provides Business Update
Iterum Therapeutics Provides Business Update
Iterum Therapeutics Provides Business Update
Iterum Therapeutics plc (ITRM) Q3 2025 Earnings Call Transcript
Iterum Therapeutics Reports Third Quarter 2025 Financial Results
Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025
Iterum Therapeutics to Present Data at IDWeek 2025
Iterum Therapeutics Provides Business Update
Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.
ITRM Reports Results
Iterum Therapeutics plc (ITRM) Q2 2025 Earnings Call Transcript
Iterum Therapeutics Reports Second Quarter 2025 Financial Results
Iterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth
Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence